Please Wait
Applying Filters...
Menu
$ API Ref.Price (USD/KG) : 158,313Xls
Filters Filter
Cross PopUp
FILTER :

filter clear-filterReset all filters

01 3Interquim, S.A.

02 1AX Pharmaceutical Corp

03 1Aurobindo Pharma Limited

04 1Hetero Drugs Limited

05 1MSN Laboratories Private Limited

06 1MYLAN LABORATORIES LIMITED

07 1SciAnda(Changshu) Pharmaceuticals, Ltd.

08 1ScinoPharm Taiwan Ltd.

09 1Sintenovo SA de CV

10 1Viyash Life Sciences Private Limited

11 1Zydus Lifesciences Limited

filter clear-filterReset all filters

filter clear-filterReset all filters

PharmaCompass

01

arrow
AAN
Not Confirmed
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothInterquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.

ROFLUMILAST

NDC Package Code : 64552-4053

Start Marketing Date : 2011-02-28

End Marketing Date : 2025-12-31

Dosage Form (Strength) : POWDER (1kg/kg)

Marketing Category : BULK INGREDIENT

Interquim

02

arrow
AAN
Not Confirmed
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothInterquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.

ROFLUMILAST

NDC Package Code : 64552-4096

Start Marketing Date : 2011-02-28

End Marketing Date : 2025-12-31

Dosage Form (Strength) : POWDER (1kg/kg)

Marketing Category : BULK INGREDIENT

Interquim

03

arrow
AAN
Not Confirmed
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothInterquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.

ROFLUMILAST

NDC Package Code : 64552-4067

Start Marketing Date : 2011-02-28

End Marketing Date : 2025-12-31

Dosage Form (Strength) : POWDER (1kg/kg)

Marketing Category : BULK INGREDIENT

Interquim

04

AAN
Not Confirmed
arrow

08

AAN
Not Confirmed
arrow
arrow
AAN
Not Confirmed

ROFLUMILAST

NDC Package Code : 61730-0010

Start Marketing Date : 2023-12-06

End Marketing Date : 2025-12-31

Dosage Form (Strength) : POWDER (1kg/kg)

Marketing Category : BULK INGREDIENT

blank

09

AAN
Not Confirmed
arrow
arrow
AAN
Not Confirmed

ROFLUMILAST

NDC Package Code : 65015-850

Start Marketing Date : 2015-02-20

End Marketing Date : 2026-12-01

Dosage Form (Strength) : POWDER (1kg/kg)

Marketing Category : BULK INGREDIENT

blank

10

AAN
Not Confirmed
arrow
arrow
AAN
Not Confirmed

ROFLUMILAST

NDC Package Code : 65841-190

Start Marketing Date : 2025-01-02

End Marketing Date : 2026-12-31

Dosage Form (Strength) : POWDER (1kg/kg)

Marketing Category : BULK INGREDIENT

blank

Looking for 162401-32-3 / Roflumilast API manufacturers, exporters & distributors?

Roflumilast manufacturers, exporters & distributors 1

48

PharmaCompass offers a list of Roflumilast API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Roflumilast manufacturer or Roflumilast supplier for your needs.

Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Roflumilast manufacturer or Roflumilast supplier.

PharmaCompass also assists you with knowing the Roflumilast API Price utilized in the formulation of products. Roflumilast API Price is not always fixed or binding as the Roflumilast Price is obtained through a variety of data sources. The Roflumilast Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.

API | Excipient name

Roflumilast

Synonyms

162401-32-3, Daxas, 3-(cyclopropylmethoxy)-n-(3,5-dichloropyridin-4-yl)-4-(difluoromethoxy)benzamide, Daliresp, By217, Byk20869

Cas Number

162401-32-3

Unique Ingredient Identifier (UNII)

0P6C6ZOP5U

About Roflumilast

Roflumilast is an orally available, long-acting inhibitor of phosphodiesterase (PDE) type 4 (PDE4), with anti-inflammatory and potential antineoplastic activities. Upon administration, roflumilast and its active metabolite roflumilast N-oxide selectively and competitively bind to and inhibit PDE4, which leads to an increase of both intracellular levels of cyclic-3',5'-adenosine monophosphate (cAMP) and cAMP-mediated signaling. cAMP prevents phosphorylation of spleen tyrosine kinase (SYK) and abrogates activation of the PI3K/AKT/mTOR signaling pathway, which may result in the induction of apoptosis. PDE4, a member of the PDE superfamily that hydrolyses cAMP and 3',5'-cyclic guanosine monophosphate (cGMP) to their inactive 5' monophosphates, is upregulated in a variety of cancers and may contribute to chemoresistance; it also plays a key role in inflammation, especially in inflammatory airway diseases.

BY217 Manufacturers

A BY217 manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of BY217, including repackagers and relabelers. The FDA regulates BY217 manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. BY217 API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

click here to find a list of BY217 manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.

BY217 Suppliers

A BY217 supplier is an individual or a company that provides BY217 active pharmaceutical ingredient (API) or BY217 finished formulations upon request. The BY217 suppliers may include BY217 API manufacturers, exporters, distributors and traders.

click here to find a list of BY217 suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.

BY217 NDC

National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing BY217 as an active pharmaceutical ingredient (API).

Finished drug products

The FDA updates the NDC directory daily. The NDC numbers for BY217 API and other APIs are published in this directory by the FDA.

Unfinished drugs

The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.

Pharmaceutical companies that manufacture BY217 as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.

Compounded drug products

The NDC directory also contains data on finished compounded human drug products that contain BY217 and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a BY217 NDC to their finished compounded human drug products, they may choose to do so.

click here to find a list of BY217 suppliers with NDC on PharmaCompass.

BY217 Manufacturers | Traders | Suppliers

BY217 Manufacturers, Traders, Suppliers 1
Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.